Neurokinin A
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597610

CAS#: 86933-74-6

Description: Neurokinin A is a mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.


Chemical Structure

img
Neurokinin A
CAS# 86933-74-6

Theoretical Analysis

MedKoo Cat#: 597610
Name: Neurokinin A
CAS#: 86933-74-6
Chemical Formula: C50H80N14O14S
Exact Mass: 1,132.57
Molecular Weight: 1,133.330
Elemental Analysis: C, 52.99; H, 7.12; N, 17.30; O, 19.76; S, 2.83

Price and Availability

Size Price Availability Quantity
1mg USD 340
5mg USD 960
Bulk inquiry

Synonym: Neurokinin A; Substance K; Neuromedin L;

IUPAC/Chemical Name: (5S,8S,14S,17S,20S,23S)-23-((2S,3R)-2-((S)-6-amino-2-((S)-2-amino-3-(1H-imidazol-4-yl)propanamido)hexanamido)-3-hydroxybutanamido)-17-benzyl-5-carbamoyl-20-(hydroxymethyl)-8-isobutyl-14-isopropyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic acid

InChi Key: HEAUFJZALFKPBA-JPQUDPSNSA-N

InChi Code: InChI=1S/C50H80N14O14S/c1-26(2)18-34(45(73)58-32(42(53)70)15-17-79-6)57-38(67)23-55-49(77)40(27(3)4)63-47(75)35(19-29-12-8-7-9-13-29)60-48(76)37(24-65)62-46(74)36(21-39(68)69)61-50(78)41(28(5)66)64-44(72)33(14-10-11-16-51)59-43(71)31(52)20-30-22-54-25-56-30/h7-9,12-13,22,25-28,31-37,40-41,65-66H,10-11,14-21,23-24,51-52H2,1-6H3,(H2,53,70)(H,54,56)(H,55,77)(H,57,67)(H,58,73)(H,59,71)(H,60,76)(H,61,78)(H,62,74)(H,63,75)(H,64,72)(H,68,69)/t28-,31+,32+,33+,34+,35+,36+,37+,40+,41+/m1/s1

SMILES Code: CSCC[C@@H](C(N)=O)NC([C@H](CC(C)C)NC(CNC([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@H](CO)NC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCCCN)NC([C@H](CC2=CNC=N2)N)=O)=O)=O)=O)=O)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,133.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jankowska E, Błaszak M, Kowalik-Jankowska T. Copper(II) complexes of neurokinin A with point mutation (S5A) and products of copper-catalyzed oxidation; role of serine residue in peptides containing neurokinin A sequence. J Inorg Biochem. 2013 Apr;121:1-9. doi: 10.1016/j.jinorgbio.2012.11.010. Epub 2012 Dec 7. PubMed PMID: 23314592.

2: Kowalik-Jankowska T, Jankowska E, Szewczuk Z, Kasprzykowski F. Coordination abilities of neurokinin A and its derivative and products of metal-catalyzed oxidation. J Inorg Biochem. 2010 Aug;104(8):831-42. doi: 10.1016/j.jinorgbio.2010.03.016. Epub 2010 Apr 11. PubMed PMID: 20435351.

3: González-Santana A, Marrero-Hernández S, Dorta I, Hernández M, Pinto FM, Báez D, Bello AR, Candenas L, Almeida TA. Altered expression of the tachykinins substance P/neurokinin A/hemokinin-1 and their preferred neurokinin 1/neurokinin 2 receptors in uterine leiomyomata. Fertil Steril. 2016 Nov;106(6):1521-1529. doi: 10.1016/j.fertnstert.2016.07.007. Epub 2016 Jul 25. PubMed PMID: 27456549.

4: Kobayashi M, Ashino S, Shiohama Y, Wakita D, Kitamura H, Nishimura T. IFN-γ elevates airway hyper-responsiveness via up-regulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model. Eur J Immunol. 2012 Feb;42(2):393-402. doi: 10.1002/eji.201141845. Epub 2011 Dec 27. PubMed PMID: 22105467.

5: Wang JM, De Ridder EF, De Potter WP, Weyns AL. Localization of neurokinin A and chromogranin A immunoreactivity in the developing porcine adrenal medulla. Histochem J. 1994 May;26(5):431-6. PubMed PMID: 8045783.

6: Duval P, Lenoir V, Moussaoui S, Garret C, Kerdelhué B. Substance P and neurokinin A variations throughout the rat estrous cycle; comparison with ovariectomized and male rats: I. Plasma, hypothalamus, anterior and posterior pituitary. J Neurosci Res. 1996 Sep 1;45(5):598-609. PubMed PMID: 8875324.

7: Bremer AA, Tansky MF, Wu M, Boyd ND, Leeman SE. Direct evidence for the interaction of neurokinin A with the tachykinin NK(1) receptor in tissue. Eur J Pharmacol. 2001 Jul 6;423(2-3):143-7. PubMed PMID: 11448478.

8: Reid MS, Herrera-Marschitz M, Ungerstedt U. Effects of intranigral substance P and neurokinin A on striatal dopamine release--II. Interactions with bicuculline and naloxone. Neuroscience. 1990;36(3):659-67. PubMed PMID: 1700330.

9: Yamamura T, Wakabayashi Y, Ohkura S, Navarro VM, Okamura H. Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats. J Reprod Dev. 2015;61(1):20-9. doi: 10.1262/jrd.2014-109. Epub 2014 Oct 27. PubMed PMID: 25345909; PubMed Central PMCID: PMC4354227.

10: Sun J, Usune S, Zhao Y, Migita K, Katsuragi T. Multidrug resistance protein transporter and Ins(1,4,5)P₃-sensitive Ca²+-signaling involved in adenosine triphosphate export via Gq protein-coupled NK₂-receptor stimulation with neurokinin A. J Pharmacol Sci. 2010;114(1):92-8. Epub 2010 Aug 21. PubMed PMID: 20736509.

11: Schelfhout V, Van De Velde V, Pauwels R, Joos G. The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction. Pulm Pharmacol Ther. 2008;21(2):276-84. Epub 2007 May 24. PubMed PMID: 17611132.

12: Yashpal K, Hui-Chan CW, Henry JL. SR 48968 specifically depresses neurokinin A- vs. substance P-induced hyperalgesia in a nociceptive withdrawal reflex. Eur J Pharmacol. 1996 Jul 11;308(1):41-8. PubMed PMID: 8836630.

13: Wang Y, Badgery-Parker T, Lovas S, Chartrel N, Vaudry H, Burcher E, Conlon JM. Primary structure and receptor-binding properties of a neurokinin A-related peptide from frog gut. Biochem J. 1992 Nov 1;287 ( Pt 3):827-32. PubMed PMID: 1332683; PubMed Central PMCID: PMC1133082.

14: Goso C, Astolfi M, Parlani M, Manzini S. [3H][beta-Ala8]neurokinin A-(4-10): a novel, selective radioligand for the tachykinin NK2 receptor. Eur J Pharmacol. 1995 Dec 27;294(1):239-45. PubMed PMID: 8788437.

15: Taniguchi T, Ninomiya H, Fukunaga R, Ebii K, Yamamoto M, Fujiwara M. Neurokinin A-stimulated phosphoinositide breakdown in rabbit iris sphincter muscle. Jpn J Pharmacol. 1992 Jun;59(2):213-20. PubMed PMID: 1279251.

16: Oh-ishi T, Shimoda T, Hayashi H, Onaga T. Role of tachykinins and neurokinin receptor subtypes in the regulation of motility of the forestomach and abomasum in conscious sheep. Neuropeptides. 2013 Feb;47(1):9-18. doi: 10.1016/j.npep.2012.07.005. Epub 2012 Aug 29. PubMed PMID: 22938860.

17: Reid MS, Herrera-Marschitz M, Hökfelt T, Ohlin M, Valentino KL, Ungerstedt U. Effects of intranigral substance P and neurokinin A on striatal dopamine release--I. Interactions with substance P antagonists. Neuroscience. 1990;36(3):643-58. PubMed PMID: 1700329.

18: Wong CM, Boyle EM, Stephen RI, Smith J, Stenson BJ, McIntosh N, Laing IA. Normative values of substance P and neurokinin A in neonates. Ann Clin Biochem. 2010 Jul;47(Pt 4):331-5. doi: 10.1258/acb.2010.010024. PubMed PMID: 20592332.

19: Moussaoui SM, Le Prado N, Bonici B, Faucher DC, Cuiné F, Laduron PM, Garret C. Distribution of neurokinin B in rat spinal cord and peripheral tissues: comparison with neurokinin A and substance P and effects of neonatal capsaicin treatment. Neuroscience. 1992 Jun;48(4):969-78. PubMed PMID: 1378579.

20: Jensen J, Conlon JM. Substance-P-related and neurokinin-A-related peptides from the brain of the cod and trout. Eur J Biochem. 1992 Jun 15;206(3):659-64. PubMed PMID: 1376687.